Login to Your Account

Front-Line sNDA Filing By Next Year

Millennium: Positive Velcade Phase III Results In New MM

By Randall Osborne

Wednesday, September 19, 2007
The early stop thanks to efficacy of Millennium Pharmaceuticals Inc.'s Phase III trial with Velcade in new multiple myeloma patients left a key question unanswered, as the firm rolls toward a supplemental new drug application in the front-line setting "as fast we can, but by the first quarter of 2008," said Deborah Dunsire, president and CEO. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription